CN102580170A - Medicinal coating stent - Google Patents
Medicinal coating stent Download PDFInfo
- Publication number
- CN102580170A CN102580170A CN2012100336795A CN201210033679A CN102580170A CN 102580170 A CN102580170 A CN 102580170A CN 2012100336795 A CN2012100336795 A CN 2012100336795A CN 201210033679 A CN201210033679 A CN 201210033679A CN 102580170 A CN102580170 A CN 102580170A
- Authority
- CN
- China
- Prior art keywords
- medicine
- stent
- blood vessels
- coating stent
- medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Interventional therapy at the bifurcation of blood vessels is a difficult point in clinic, and particularly stents in the bifurcated blood vessels are difficult to introduce, and the restenosis rate is high in the later period due to high possibility of pathological changes such as thrombus, intimal hyperplasia and the like. Aiming at the problem, the invention provides a design scheme of the medicinal coating stent. In the design scheme, a section of part of which has the medicinal concentration is uniform and is higher than that of other parts is positioned in the stent; and the part with the high medicinal concentration corresponds to inlets of the bifurcated blood vessels, so that medicinal ingredients act on the bifurcated blood vessels, excessive medicinal ingredients can be applied in main blood vessels, the probability of the pathological changes such as thrombus, intimal hyperplasia and the like in the bifurcated blood vessels is reduced, and the operation of implanting the stent in the bifurcated blood vessels independently is avoided.
Description
Technical field
The present invention relates to a kind of coating stent of medicine, particularly a kind of coating stent of medicine that is used for the vascular bifurcation place.
Background technology
The subject matter that present coronary artery bracket interventional therapy faces is later stage in-stent restenosis problem, and is wherein outstanding with arteria coronaria crotch in-stent restenosis especially.1,000,000 routine percutaneous arteria coronaria interventions are arranged global every year approximately, and (arteria coronaria bifurcated lesions interventional therapy accounts for 20% of PCI sum for Percutaneous coronary intervention, PCI) treatment patient, and the incidence rate of its in-stent restenosis is up to 30%.Trace it to its cause, on the one hand: vascular bifurcation position blood flow is unstable, and it is very complicated that support is implanted the mechanical environment of back blood vessel crotch, brings out pathological changes such as atherosclerosis, thrombosis speckle easily.On the other hand, the support at vascular bifurcation place is implanted and is located also and implant difficulty than the wall scroll endovascular stent.If main blood vessel (Main artery; MA) and bifurcated vessels (Branch artery; BA) all need implant frame, also having a support so between two parts support can not region covered (Ancovered Area) become multiple position such as postoperative thrombosis speckle, neointimal hyperplasia.Seek the interventional therapy method at vascular bifurcation place, reduce the interior restenosis rate of restenosis rate, particularly bifurcated vessels at vascular bifurcation place, become difficult point problem clinical and scientific research circle research.
Receive washing away of unidirectional blood flow behind the coating stent of medicine implantable intravascular, the rate of release of ingredient and the regularity of distribution can receive the influence of the partial hemodynamics environment of blood vessel.If can utilize the hemodynamics characteristic at vascular bifurcation place; The distribution of drug level on the appropriate design support; The ingredient that the coating stent of medicine that winner's blood vessel is implanted into discharges can get in the bifurcated vessels in right amount; The generation of untoward reaction such as the formation that will help suppressing thrombosis in the bifurcated vessels and neointimal hyperplasia, the vascular restenosis rate behind the reduction interventional therapy.
Summary of the invention
The present invention is directed to the deficiency that prior art exists, propose a kind of new coating stent of medicine that is used for vascular bifurcation place interventional therapy.Behind the master's blood vessel of this support implantable intravascular bifurcation; The ingredient that discharges on the coating stent of medicine gets into bifurcated vessels more; Reach the generation that suppresses thrombosis, neointimal hyperplasia class pathological changes in the bifurcated vessels, reduce the purpose of vascular bifurcation position interventional therapy restenosis rate.
In order to solve the problems of the technologies described above, the present invention realizes through following technical scheme: a kind of novel medicament coating bracket, this coating stent of medicine exist one section drug level evenly and be higher than the part at other position.
Said coating stent of medicine comprises holder part and medication coat part.
The holder part of said coating stent of medicine can be that metal rack also can be the degradation material support.
Said medication coat is formed by polymer with by the ingredient of polymer overmold.
Said ingredient is a type or the combination of 2-4 class in statins, rapamycin class, taxanes, the heparin class medicine.
Said coating stent of medicine drug level evenly and the axial length of part that is higher than other position greater than 0 and less than the support total length.
Through technique scheme, can keep coating stent of medicine implantable intravascular bifurcation after, the medicine that partly discharges with the corresponding high drug level of bifurcated vessels inlet is more must to get into bifurcated vessels, thereby suppresses the generation of the interior restenosis of bifurcated vessels.
Description of drawings:
Fig. 1 is a front view of the present invention;
Fig. 2 is the relative position figure behind the implantable intravascular of the present invention bifurcation.
Among the figure: 1 coating stent of medicine; 2 coating stent of medicine drug level evenly and be higher than the part at other position; 3 main blood vessels; 4 bifurcated vessels.
Specific embodiments
The specific embodiment of the present invention is explained as follows:
As shown in Figure 1, coating stent of medicine 1 disclosed by the invention has the shape of intravascular stent, and it is made up of the two large divisions: holder part and medication coat part.Wherein holder part can be metal rack or biodegradable stent, the form of presentation or the shape of disclosed intravascular stent before its form of presentation or shape can adopt.The medication coat part is made up of two parts again: polymer and ingredient.Wherein polymer can adopt the component of polymer on disclosed coating stent of medicine surface, and ingredient is the combination of a kind of or 2-4 kind in statins, rapamycin class, taxanes, the heparin class medicine.Support exists one section drug level evenly and be higher than the part 2 at other position, and the length of this part is greater than 0 and less than the total length of coating stent of medicine 1.In concrete the use, this intravascular stent is implanted in the main blood vessel 3 at vascular bifurcation position, as shown in Figure 2.Concentration evenly and be higher than the inlet of the just corresponding bifurcated vessels 4 of part 2 at other position.
Through the enforcement of above technical scheme, have more medicine and under the effect of blood flow, affact bifurcated vessels 4, apply the overdose of medicine thing in again can be in the drug dose in guaranteeing bifurcated vessels 4 to main blood vessel 3.This has just suppressed the generation of interior thrombosis of bifurcated vessels and neointimal hyperplasia class pathological changes.For the lower situation of stenosis in the bifurcated vessels, also can avoid being implanted into intravascular stent at bifurcated vessels, reduce operative complications and patient medical expense.
Claims (5)
1. coating stent of medicine comprises holder part and applies superincumbent medication coat, it is characterized in that, said coating stent of medicine exists one section drug level evenly and be higher than the part at other position.
2. coating stent of medicine according to claim 1 is characterized in that, the holder part of said coating stent of medicine can be that metal rack also can be the degradation material support.
3. coating stent of medicine according to claim 1 is characterized in that, said medication coat is formed by polymer with by the ingredient of polymer overmold.
4. coating stent of medicine according to claim 1 is characterized in that, the ingredient of said medication coat is a type or the combination of 2-4 class in statins, rapamycin class, taxanes, the heparin class medicine.
5. coating stent of medicine according to claim 1 is characterized in that, said coating stent of medicine drug level evenly and the axial length of part that is higher than other position greater than 0 and less than the support total length.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100336795A CN102580170A (en) | 2012-02-15 | 2012-02-15 | Medicinal coating stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100336795A CN102580170A (en) | 2012-02-15 | 2012-02-15 | Medicinal coating stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102580170A true CN102580170A (en) | 2012-07-18 |
Family
ID=46469756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100336795A Pending CN102580170A (en) | 2012-02-15 | 2012-02-15 | Medicinal coating stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102580170A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
| WO2008098418A1 (en) * | 2007-02-14 | 2008-08-21 | Shandong Intech Medical Technology Co., Ltd. | Intracoronary stent with asymmetric drug releasing controlled coating |
-
2012
- 2012-02-15 CN CN2012100336795A patent/CN102580170A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
| WO2008098418A1 (en) * | 2007-02-14 | 2008-08-21 | Shandong Intech Medical Technology Co., Ltd. | Intracoronary stent with asymmetric drug releasing controlled coating |
Non-Patent Citations (1)
| Title |
|---|
| 郭萌等: "药物洗脱支架置入弯曲冠状动脉血管后药物浓度场及壁面切应力分布", 《中国组织工程研究与临床康复》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heldman et al. | Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis | |
| Kolandaivelu et al. | Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings | |
| Ma et al. | Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies | |
| Rogers et al. | Endovascular stent design dictates experimental restenosis and thrombosis | |
| JP5675611B2 (en) | Implantable medical devices coated with biodegradable elastomers and releasable taxanes | |
| Grube et al. | TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions | |
| JP5329435B2 (en) | Coronary stent with asymmetric drug release controlled coating | |
| CN103948975B (en) | A kind of targeted drug release gets involved class medical apparatus and instruments and preparation method thereof | |
| Wu et al. | Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| Lewis | Materials, fluid dynamics, and solid mechanics aspects of coronary artery stents: A state‐of‐the‐art review | |
| CN105944155A (en) | Drug eluting stent and manufacturing method and application thereof | |
| Lancaster et al. | Microrough cobalt–chromium alloy surfaces for paclitaxel delivery: preparation, characterization, and in vitro drug release studies | |
| Zhang et al. | Multistep instead of one-step: a versatile and multifunctional coating platform for biocompatible corrosion protection | |
| CN108114326A (en) | A kind of two-way double bracket for eluting medicament and preparation method thereof | |
| Miswan et al. | Drug-eluting coating of ginsenoside Rg1 and Re incorporated poly (lactic-co-glycolic acid) on stainless steel 316L: Physicochemical and drug release analyses | |
| CN104107459A (en) | Degradable polymer coating support with sequential response function, and making method thereof | |
| Patel et al. | Current status and future prospects of drug eluting stents for restenosis/Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove | |
| CN107496998B (en) | Peripheral drug eluting stent and preparation and application thereof | |
| US20120150282A1 (en) | Implant having a paclitaxel-releasing coating | |
| CN101584888A (en) | Medicament release intravascular stent and preparation method thereof | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| CN102580170A (en) | Medicinal coating stent | |
| CN101641059A (en) | Intracoronary stent with asymmetric drug releasing controlled coating | |
| CN101496813A (en) | Anti-hyperblastosis (vascular restenosis) composition and application method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120718 |